cumulative AUC

7 messages 6 people Latest: Nov 20, 2019

cumulative AUC

From: Sam Liao Date: November 08, 2019 technical
Dear nmusers, I have a question how to reset cumulative AUC in a $DES model, where DADT(4) is set up as cumulative AUC of C1. Because the study is a four way crossover study, the cumulative value of A(4) need to rest to zero before each subsequent treatments. However, NONMEM do not allow setting A(4) to zero in the statement of control stream. Is there any work around of this problem? Best regards, Sam Liao
Quoted reply history
On 11/7/2019 7:17 AM, Farrell, Colm wrote: > At ICON, it’s our people that set us apart. > > As a global provider of drug development solutions, our work is serious business. But that doesn’t mean you can’t have fun while you do it. With our vision to be the partner of choice in drug development, we hire only the best and brightest in the industry. Are you one of them? > > Due to the continuing demand to support our clients in drug development through the integration of modelling and simulation into clinical development programs, ICON is looking for an experienced pharmacometrician to join our global PKPDM&S team, with a key responsibility to develop and apply M&S strategies, study designs and analyses across all phases of drug development. With members of the PKPDM&S based in UK and USA, we’re flexible on the location. > > *The role* > > ·Prepare PKPDM&S-based strategies to support clinical development programs; > > ·Design, conduct, interpret and prepare appropriate study and regulatory summaries of PKPDM&S activities; > > ·Build and sustain great relationships with clients; > > ·Prepare and present scientific publications; > > ·Serve as scientific reviewer and staff mentor to colleagues. > > *What you need* > > ·PhD (or equivalent experience) in pharmacokinetics/PKPD with proven industry or academic post PhD experience; > > ·Excellent understanding of the integration of PKPDM&S into clinical drug development > > ·Demonstrated expertise in hands-on population-based modelling e.g. NONMEM, Monolix and related software (R, Xpose, PsN); > > ·Proven mentorship capabilities. > > *Why join us* > > ICON enjoys a strong reputation for quality and is focused on staff development. We make it our mission to attract the most diverse and creative minds into the business and we continually strive to provide opportunities for our people to excel, grow and build a phenomenal career. We understand that our greatest asset is the skills and talents of our people and they are truly what set us apart. Other than working with a great team of switched on and ambitious people, we also offer a very competitive benefits package. This varies from country to country so a dedicated recruiter will discuss this with you at interview stage. We care about our people as they are the key to our success. We provide an open and friendly work environment where we empower people and provide them with opportunities to develop their long term career. ICON is an equal opportunity employer - M/F/D/V and committed to providing a workplace free of any discrimination or harassment. > > To find out more and apply for the role, please visit: https://icon.wd3.myworkdayjobs.com/broadbean_external/job/UK-London-Marlow/Senior-PK-Scientist-II_061382-1 > >

Re: cumulative AUC

From: Rob ter Heine Date: November 08, 2019 technical
Hi Sam, You can activate a flag from 0 to 1 from a certain timepoint (eg FLA1) and integrate the auc as follows Datdt(x)=C*FLA1 Rob
Quoted reply history
Op 8 nov. 2019 om 19:16 heeft Sam Liao <sliao_at_pharmaxresearch.com> het volgende geschreven:  Dear nmusers, I have a question how to reset cumulative AUC in a $DES model, where DADT(4) is set up as cumulative AUC of C1. Because the study is a four way crossover study, the cumulative value of A(4) need to rest to zero before each subsequent treatments. However, NONMEM do not allow setting A(4) to zero in the statement of control stream. Is there any work around of this problem? Best regards, Sam Liao On 11/7/2019 7:17 AM, Farrell, Colm wrote: At ICON, it’s our people that set us apart. As a global provider of drug development solutions, our work is serious business. But that doesn’t mean you can’t have fun while you do it. With our vision to be the partner of choice in drug development, we hire only the best and brightest in the industry. Are you one of them? Due to the continuing demand to support our clients in drug development through the integration of modelling and simulation into clinical development programs, ICON is looking for an experienced pharmacometrician to join our global PKPDM&S team, with a key responsibility to develop and apply M&S strategies, study designs and analyses across all phases of drug development. With members of the PKPDM&S based in UK and USA, we’re flexible on the location. The role · Prepare PKPDM&S-based strategies to support clinical development programs; · Design, conduct, interpret and prepare appropriate study and regulatory summaries of PKPDM&S activities; · Build and sustain great relationships with clients; · Prepare and present scientific publications; · Serve as scientific reviewer and staff mentor to colleagues. What you need · PhD (or equivalent experience) in pharmacokinetics/PKPD with proven industry or academic post PhD experience; · Excellent understanding of the integration of PKPDM&S into clinical drug development · Demonstrated expertise in hands-on population-based modelling e.g. NONMEM, Monolix and related software (R, Xpose, PsN); · Proven mentorship capabilities. Why join us ICON enjoys a strong reputation for quality and is focused on staff development. We make it our mission to attract the most diverse and creative minds into the business and we continually strive to provide opportunities for our people to excel, grow and build a phenomenal career. We understand that our greatest asset is the skills and talents of our people and they are truly what set us apart. Other than working with a great team of switched on and ambitious people, we also offer a very competitive benefits package. This varies from country to country so a dedicated recruiter will discuss this with you at interview stage. We care about our people as they are the key to our success. We provide an open and friendly work environment where we empower people and provide them with opportunities to develop their long term career. ICON is an equal opportunity employer - M/F/D/V and committed to providing a workplace free of any discrimination or harassment. To find out more and apply for the role, please visit: https://icon.wd3.myworkdayjobs.com/broadbean_external/job/UK-London-Marlow/Senior-PK-Scientist-II_061382-1

Re: cumulative AUC

From: Rob ter Heine Date: November 08, 2019 technical
Hi Sam, You can activate a flag from 0 to 1 from a certain timepoint (eg FLA1) and integrate the auc as follows Datdt(x)=C*FLA1 Rob Op 8 nov. 2019 om 19:16 heeft Sam Liao <[email protected]> het volgende geschreven:  Dear nmusers, I have a question how to reset cumulative AUC in a $DES model, where DADT(4) is set up as cumulative AUC of C1. Because the study is a four way crossover study, the cumulative value of A(4) need to rest to zero before each subsequent treatments. However, NONMEM do not allow setting A(4) to zero in the statement of control stream. Is there any work around of this problem? Best regards, Sam Liao
Quoted reply history
On 11/7/2019 7:17 AM, Farrell, Colm wrote: At ICON, it’s our people that set us apart. As a global provider of drug development solutions, our work is serious business. But that doesn’t mean you can’t have fun while you do it. With our vision to be the partner of choice in drug development, we hire only the best and brightest in the industry. Are you one of them? Due to the continuing demand to support our clients in drug development through the integration of modelling and simulation into clinical development programs, ICON is looking for an experienced pharmacometrician to join our global PKPDM&S team, with a key responsibility to develop and apply M&S strategies, study designs and analyses across all phases of drug development. With members of the PKPDM&S based in UK and USA, we’re flexible on the location. The role · Prepare PKPDM&S-based strategies to support clinical development programs; · Design, conduct, interpret and prepare appropriate study and regulatory summaries of PKPDM&S activities; · Build and sustain great relationships with clients; · Prepare and present scientific publications; · Serve as scientific reviewer and staff mentor to colleagues. What you need · PhD (or equivalent experience) in pharmacokinetics/PKPD with proven industry or academic post PhD experience; · Excellent understanding of the integration of PKPDM&S into clinical drug development · Demonstrated expertise in hands-on population-based modelling e.g. NONMEM, Monolix and related software (R, Xpose, PsN); · Proven mentorship capabilities. Why join us ICON enjoys a strong reputation for quality and is focused on staff development. We make it our mission to attract the most diverse and creative minds into the business and we continually strive to provide opportunities for our people to excel, grow and build a phenomenal career. We understand that our greatest asset is the skills and talents of our people and they are truly what set us apart. Other than working with a great team of switched on and ambitious people, we also offer a very competitive benefits package. This varies from country to country so a dedicated recruiter will discuss this with you at interview stage. We care about our people as they are the key to our success. We provide an open and friendly work environment where we empower people and provide them with opportunities to develop their long term career. ICON is an equal opportunity employer - M/F/D/V and committed to providing a workplace free of any discrimination or harassment. To find out more and apply for the role, please visit: https://icon.wd3.myworkdayjobs.com/broadbean_external/job/UK-London-Marlow/Senior-PK-Scientist-II_061382-1

Re: cumulative AUC

From: Leonid Gibiansky Date: November 08, 2019 technical
Negative CMT (in the data set) resets compartment amounts (CMT=-4 in this case) EVID = 4 resets all system, including A(4) (if washout time was long and all compartments can be set to 0) Also, it is easy to do post-processing, subtracting Cycle 1 AUC from Cycle 1-2 AUC to get Cycle 2 AUC, etc. Hope this helps Leonid
Quoted reply history
On 11/8/2019 12:59 PM, Sam Liao wrote: > Dear nmusers, > > I have a question how to reset cumulative AUC in a $DES model, where DADT(4) is set up as cumulative AUC of C1. > > Because the study is a four way crossover study, the cumulative value of A(4) need to rest to zero before each subsequent treatments. > > However, NONMEM do not allow setting A(4) to zero in the statement of control stream. > > Is there any work around of this problem? > > Best regards, > > Sam Liao > > On 11/7/2019 7:17 AM, Farrell, Colm wrote: > > > At ICON, it’s our people that set us apart. > > > > As a global provider of drug development solutions, our work is serious business. But that doesn’t mean you can’t have fun while you do it. With our vision to be the partner of choice in drug development, we hire only the best and brightest in the industry. Are you one of them? > > > > Due to the continuing demand to support our clients in drug development through the integration of modelling and simulation into clinical development programs, ICON is looking for an experienced pharmacometrician to join our global PKPDM&S team, with a key responsibility to develop and apply M&S strategies, study designs and analyses across all phases of drug development. With members of the PKPDM&S based in UK and USA, we’re flexible on the location. > > > > *The role* > > > > ·Prepare PKPDM&S-based strategies to support clinical development programs; > > > > ·Design, conduct, interpret and prepare appropriate study and regulatory summaries of PKPDM&S activities; > > > > ·Build and sustain great relationships with clients; > > > > ·Prepare and present scientific publications; > > > > ·Serve as scientific reviewer and staff mentor to colleagues. > > > > *What you need* > > > > ·PhD (or equivalent experience) in pharmacokinetics/PKPD with proven industry or academic post PhD experience; > > > > ·Excellent understanding of the integration of PKPDM&S into clinical drug development > > > > ·Demonstrated expertise in hands-on population-based modelling e.g. NONMEM, Monolix and related software (R, Xpose, PsN); > > > > ·Proven mentorship capabilities. > > > > *Why join us* > > > > ICON enjoys a strong reputation for quality and is focused on staff development. We make it our mission to attract the most diverse and creative minds into the business and we continually strive to provide opportunities for our people to excel, grow and build a phenomenal career. We understand that our greatest asset is the skills and talents of our people and they are truly what set us apart. Other than working with a great team of switched on and ambitious people, we also offer a very competitive benefits package. This varies from country to country so a dedicated recruiter will discuss this with you at interview stage. We care about our people as they are the key to our success. We provide an open and friendly work environment where we empower people and provide them with opportunities to develop their long term career. ICON is an equal opportunity employer - M/F/D/V and committed to providing a workplace free of any discrimination or harassment. > > > > To find out more and apply for the role, please visit: https://icon.wd3.myworkdayjobs.com/broadbean_external/job/UK-London-Marlow/Senior-PK-Scientist-II_061382-1 > > > >

Re: cumulative AUC

From: Ruben Faelens Date: November 08, 2019 technical
Hi Sam, Can't you simply dose with evid=4 (reset) into your auc compartment (cmt=4)? Op vr 8 nov. 2019 19:09 schreef Sam Liao <[email protected]>: > Dear nmusers, > > I have a question how to reset cumulative AUC in a $DES model, where > DADT(4) is set up as cumulative AUC of C1. > > Because the study is a four way crossover study, the cumulative value of > A(4) need to rest to zero before each subsequent treatments. > > However, NONMEM do not allow setting A(4) to zero in the statement of > control stream. > > Is there any work around of this problem? > > Best regards, > > Sam Liao
Quoted reply history
> On 11/7/2019 7:17 AM, Farrell, Colm wrote: > > At ICON, it’s our people that set us apart. > > As a global provider of drug development solutions, our work is serious > business. But that doesn’t mean you can’t have fun while you do it. With > our vision to be the partner of choice in drug development, we hire only > the best and brightest in the industry. Are you one of them? > > Due to the continuing demand to support our clients in drug development > through the integration of modelling and simulation into clinical > development programs, ICON is looking for an experienced pharmacometrician > to join our global PKPDM&S team, with a key responsibility to develop and > apply M&S strategies, study designs and analyses across all phases of drug > development. With members of the PKPDM&S based in UK and USA, we’re > flexible on the location. > > *The role* > > · Prepare PKPDM&S-based strategies to support clinical > development programs; > > · Design, conduct, interpret and prepare appropriate study and > regulatory summaries of PKPDM&S activities; > > · Build and sustain great relationships with clients; > > · Prepare and present scientific publications; > > · Serve as scientific reviewer and staff mentor to colleagues. > > *What you need* > > · PhD (or equivalent experience) in pharmacokinetics/PKPD with > proven industry or academic post PhD experience; > > · Excellent understanding of the integration of PKPDM&S into > clinical drug development > > · Demonstrated expertise in hands-on population-based modelling > e.g. NONMEM, Monolix and related software (R, Xpose, PsN); > > · Proven mentorship capabilities. > > *Why join us* > > ICON enjoys a strong reputation for quality and is focused on staff > development. We make it our mission to attract the most diverse and > creative minds into the business and we continually strive to provide > opportunities for our people to excel, grow and build a phenomenal career. > We understand that our greatest asset is the skills and talents of our > people and they are truly what set us apart. Other than working with a > great team of switched on and ambitious people, we also offer a very > competitive benefits package. This varies from country to country so a > dedicated recruiter will discuss this with you at interview stage. We care > about our people as they are the key to our success. We provide an open and > friendly work environment where we empower people and provide them with > opportunities to develop their long term career. ICON is an equal > opportunity employer - M/F/D/V and committed to providing a workplace free > of any discrimination or harassment. > > To find out more and apply for the role, please visit: > https://icon.wd3.myworkdayjobs.com/broadbean_external/job/UK-London-Marlow/Senior-PK-Scientist-II_061382-1 > > > > >

Re: cumulative AUC

From: Matt Fidler Date: November 08, 2019 technical
Hi Sam, Leonid is correct, you have to turn it off and then back on again. https://nlmixrdevelopment.github.io/RxODE/articles/RxODE-event-types.html#turning-off-compartments shows a visual example. Matt.
Quoted reply history
On Fri, Nov 8, 2019 at 1:12 PM Leonid Gibiansky <[email protected]> wrote: > actually CMT=-4 turns compartment 4 off. It need to be turned on again, > see by the record with CMT=4 (positive), see > > Plasma urine example > > in Nonmem help > > Leonid > > On 11/8/2019 1:47 PM, Leonid Gibiansky wrote: > > Negative CMT (in the data set) resets compartment amounts (CMT=-4 in > > this case) > > EVID = 4 resets all system, including A(4) (if washout time was long > > and all compartments can be set to 0) > > Also, it is easy to do post-processing, subtracting Cycle 1 AUC from > > Cycle 1-2 AUC to get Cycle 2 AUC, etc. > > Hope this helps > > Leonid > > > > On 11/8/2019 12:59 PM, Sam Liao wrote: > >> Dear nmusers, > >> > >> I have a question how to reset cumulative AUC in a $DES model, where > >> DADT(4) is set up as cumulative AUC of C1. > >> > >> Because the study is a four way crossover study, the cumulative value > >> of A(4) need to rest to zero before each subsequent treatments. > >> > >> However, NONMEM do not allow setting A(4) to zero in the statement of > >> control stream. > >> > >> Is there any work around of this problem? > >> > >> Best regards, > >> > >> Sam Liao > >> > >> On 11/7/2019 7:17 AM, Farrell, Colm wrote: > >>> > >>> At ICON, it’s our people that set us apart. > >>> > >>> As a global provider of drug development solutions, our work is > >>> serious business. But that doesn’t mean you can’t have fun while you > >>> do it. With our vision to be the partner of choice in drug > >>> development, we hire only the best and brightest in the industry. Are > >>> you one of them? > >>> > >>> Due to the continuing demand to support our clients in drug > >>> development through the integration of modelling and simulation into > >>> clinical development programs, ICON is looking for an experienced > >>> pharmacometrician to join our global PKPDM&S team, with a key > >>> responsibility to develop and apply M&S strategies, study designs and > >>> analyses across all phases of drug development. With members of the > >>> PKPDM&S based in UK and USA, we’re flexible on the location. > >>> > >>> *The role* > >>> > >>> ·Prepare PKPDM&S-based strategies to support clinical development > >>> programs; > >>> > >>> ·Design, conduct, interpret and prepare appropriate study and > >>> regulatory summaries of PKPDM&S activities; > >>> > >>> ·Build and sustain great relationships with clients; > >>> > >>> ·Prepare and present scientific publications; > >>> > >>> ·Serve as scientific reviewer and staff mentor to colleagues. > >>> > >>> *What you need* > >>> > >>> ·PhD (or equivalent experience) in pharmacokinetics/PKPD with proven > >>> industry or academic post PhD experience; > >>> > >>> ·Excellent understanding of the integration of PKPDM&S into clinical > >>> drug development > >>> > >>> ·Demonstrated expertise in hands-on population-based modelling e.g. > >>> NONMEM, Monolix and related software (R, Xpose, PsN); > >>> > >>> ·Proven mentorship capabilities. > >>> > >>> *Why join us* > >>> > >>> ICON enjoys a strong reputation for quality and is focused on staff > >>> development. We make it our mission to attract the most diverse and > >>> creative minds into the business and we continually strive to provide > >>> opportunities for our people to excel, grow and build a phenomenal > >>> career. We understand that our greatest asset is the skills and > >>> talents of our people and they are truly what set us apart. Other > >>> than working with a great team of switched on and ambitious people, > >>> we also offer a very competitive benefits package. This varies from > >>> country to country so a dedicated recruiter will discuss this with > >>> you at interview stage. We care about our people as they are the key > >>> to our success. We provide an open and friendly work environment > >>> where we empower people and provide them with opportunities to > >>> develop their long term career. ICON is an equal opportunity employer > >>> - M/F/D/V and committed to providing a workplace free of any > >>> discrimination or harassment. > >>> > >>> To find out more and apply for the role, please visit: > >>> > https://icon.wd3.myworkdayjobs.com/broadbean_external/job/UK-London-Marlow/Senior-PK-Scientist-II_061382-1 > >>> > >>> > >>> > >>> > >>>

RE: cumulative AUC

From: Dongfen Yuan Date: November 20, 2019 technical
Hi Ruben, This may not be a good idea: 1) evid = 4 reset all compartments; 2) when evid = 4, CMT is meant for dosing compartment (in my understanding, never tried). Please see the nonmem CMT PCMT data item help page. Best regards, Dongfen Yuan PK Scientist Parexel International 2520 Meridian Parkway Durham, NC 27713, USA t +1 919 748 6054 [email protected]<mailto:[email protected]> This communication, including any attachments, is intended only for the person or entity to which it is addressed and may contain confidential information. Any review, retransmission, distribution or other use of this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please destroy any copies, contact the sender and delete the information from any computer. Thank you.
Quoted reply history
From: [email protected] <[email protected]> On Behalf Of Ruben Faelens Sent: Friday, November 8, 2019 1:52 PM To: Sam Liao <[email protected]> Cc: NMusers <[email protected]> Subject: Re: [NMusers] cumulative AUC Hi Sam, Can't you simply dose with evid=4 (reset) into your auc compartment (cmt=4)? Op vr 8 nov. 2019 19:09 schreef Sam Liao <[email protected]<mailto:[email protected]>>: Dear nmusers, I have a question how to reset cumulative AUC in a $DES model, where DADT(4) is set up as cumulative AUC of C1. Because the study is a four way crossover study, the cumulative value of A(4) need to rest to zero before each subsequent treatments. However, NONMEM do not allow setting A(4) to zero in the statement of control stream. Is there any work around of this problem? Best regards, Sam Liao On 11/7/2019 7:17 AM, Farrell, Colm wrote: At ICON, it’s our people that set us apart. As a global provider of drug development solutions, our work is serious business. But that doesn’t mean you can’t have fun while you do it. With our vision to be the partner of choice in drug development, we hire only the best and brightest in the industry. Are you one of them? Due to the continuing demand to support our clients in drug development through the integration of modelling and simulation into clinical development programs, ICON is looking for an experienced pharmacometrician to join our global PKPDM&S team, with a key responsibility to develop and apply M&S strategies, study designs and analyses across all phases of drug development. With members of the PKPDM&S based in UK and USA, we’re flexible on the location. The role • Prepare PKPDM&S-based strategies to support clinical development programs; • Design, conduct, interpret and prepare appropriate study and regulatory summaries of PKPDM&S activities; • Build and sustain great relationships with clients; • Prepare and present scientific publications; • Serve as scientific reviewer and staff mentor to colleagues. What you need • PhD (or equivalent experience) in pharmacokinetics/PKPD with proven industry or academic post PhD experience; • Excellent understanding of the integration of PKPDM&S into clinical drug development • Demonstrated expertise in hands-on population-based modelling e.g. NONMEM, Monolix and related software (R, Xpose, PsN); • Proven mentorship capabilities. Why join us ICON enjoys a strong reputation for quality and is focused on staff development. We make it our mission to attract the most diverse and creative minds into the business and we continually strive to provide opportunities for our people to excel, grow and build a phenomenal career. We understand that our greatest asset is the skills and talents of our people and they are truly what set us apart. Other than working with a great team of switched on and ambitious people, we also offer a very competitive benefits package. This varies from country to country so a dedicated recruiter will discuss this with you at interview stage. We care about our people as they are the key to our success. We provide an open and friendly work environment where we empower people and provide them with opportunities to develop their long term career. ICON is an equal opportunity employer - M/F/D/V and committed to providing a workplace free of any discrimination or harassment. To find out more and apply for the role, please visit: https://icon.wd3.myworkdayjobs.com/broadbean_external/job/UK-London-Marlow/Senior-PK-Scientist-II_061382-1